Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 172 от 240

Предстои набиране

Residual Sleepiness and Accident Risk in Treated Obstructive Sleep Apnea

Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is a major cause of excessive daytime sleepiness and impaired vigilance, leading to an increased risk of road and occupational accidents. Despite effective treatment with continuous positive airway pressure (CPAP) or mandibular advancement devices, more than one third of treated patients report persistent subjective sleepiness and/or objective vigilance impairment. The Maintenance of Wakefulness Test (MWT) is currently considered the legal reference test for the assessment of vigilance. However, its availability is limited and does not allow systematic and regular evaluation of all patients at risk. This prospective study aims to identify determinants of residual daytime sleepiness and impaired vigilance in treated OSA, with a specific focus on the role of hypoxic burden at diagnosis. The study also aims to evaluate alternative behavioral and psychomotor tests as potential complementary tools to the MWT, and to assess their relationship with simulated driving performance and retrospective accident history.

Начало: 01.05.2026 Край: 01.05.2029 Възраст: от 18 г.

France Hospices Civils de Lyon NCT07545421

Предстои набиране

Post-Market Clinical Study Using TRAQ™ for Minimally Invasive Posterior Sacroiliac Joint Fusion

Sacroiliac Joint Dysfunction Sacroiliac Joint Pain

The purpose of this study is to evaluate the real-world performance, safety and efficacy of the TRAQ System.

Начало: 01.05.2026 Край: 01.12.2028 Възраст: от 21 г.

PainTEQ, LLC NCT07547215

Предстои набиране

Study to Evaluate the Feasibility of Syde® Digital Endpoints for Monitoring Patients With Progressive Supranuclear Palsy - Richardson Syndrome (PSP-R)

Progressive Supranuclear Palsy- Richardson Syndrome (PSP-R)

The study aims to assess the feasibility/acceptability of real-world activity monitoring by the Syde® wearable device in PSP-R. The Syde® collected data will be compared to on-site conventional clinical endpoints, including functional capacity and cognitive assessments, as well as core scales assessments.

Начало: 01.05.2026 Край: 01.03.2028 Възраст: от 18 г.

France SYSNAV NCT07389018

Предстои набиране

Using e-Technologies to Maximize Physical Activity After Cancer Treatment

Cancer

The Cancer Exercise app (CEA) is designed to promote physical activity among cancer survivors. The proposed randomized controlled clinical trial will investigate, in adults who have completed cancer treatment, the effects of a 12-week home-based exercise program, delivered using CEA, on physical activity levels. Participants will be randomized into one of two groups: (1) CEA or (2) Usual Care.

Начало: 01.05.2026 Край: 01.05.2028 Възраст: 18–85 г.

University of Florida NCT07535918

Предстои набиране

Muscle Aging Phenotypes in Childhood Cancer Survivors

Muscle Weakness Low Muscle Mass Sarcopenia

Childhood cancer survivors experience premature declines in muscle mass, strength, and physical function that contribute to morbidity and early mortality. The biological mechanisms driving these impairments are heterogeneous and poorly understood. This observational study aims to characterize distinct muscle health endotypes in adult survivors of childhood cancer using advanced imaging, neuromuscular testing, and functional assessment. Survivors with reduced muscle health and community controls will undergo multimodal magnetic resonance imaging and spectroscopy, nerve conduction studies, surface electromyography, body composition assessment, and physical performance testing during a single study visit integrated into an ongoing cohort evaluation. Identifying mechanistic endotypes of impaired muscle health will support development of targeted interventions to preserve function and improve long-term outcomes in childhood cancer survivors. Primary Objective: \- Characterize reduced muscle health endotypes in childhood cancer survivors. Secondary Objective: \- Identify specific treatment and lifestyle related risk factors for each reduced muscle health endotype. Exploratory Objective: \- Host germline genetics will be associated with specific muscle endotypes.

Начало: 01.05.2026 Край: 01.05.2031 Възраст: от 18 г.

United States St. Jude Children's Research Hospital NCT07531498

Предстои набиране

Objective Assessment of Skin Damage Using ADHELASKIN in Patients With Systemic Sclerosis

D013493

Systemic sclerosis (SSc) is an autoimmune disease characterized by skin fibrosis, which clinically manifests as thickening, hardening, and loss of elasticity of the skin. Patients are typically classified as having diffuse cutaneous SSc (dcSSc) or limited cutaneous SSc (lcSSc) depending on the extent of skin fibrosis. The standard assessment of cutaneous sclerosis is based on the modified Rodnan skin score (mRSS), which consists of clinical palpation of 17 areas of the body, scored from 0 (normal) to 3 (severe sclerosis) for each area, with a total of 51 points. However, the mRSS has several limitations, including high inter- and intra-observer variability, particularly depending on the clinician's experience, subjectivity of palpation with difficulties in quantifying subtle changes in firmness or elasticity, and limited sensitivity to small changes or in areas that are not severely affected. The assessment of skin fibrosis therefore faces a lack of objective, quantitative tools that are easy to use in routine clinical practice. Certain alternatives have been evaluated (durometer, ultrasound, elastography, etc.), but none has yet been fully adopted or validated for measuring firmness, elasticity, and adhesion at different depths of the skin with good accuracy and reproducibility. ADHELASKIN° technology (by Tactinnov, LTDS / École Centrale de Lyon) enables objective, highly sensitive measurement of rigidity, firmness and elasticity using an indentation method with a ruby ball sensor. The objective of our study is to assess whether the ADHELASKIN device can differentiate between the biomechanical properties of healthy patients and those of patients with SSc.

Начало: 01.05.2026 Край: 01.05.2027 Възраст: от 18 г.

France Centre Hospitalier Universitaire de Saint Etienne NCT07543679

Предстои набиране

The Effect of Spinal Manipulation on Heart Rate Variability in Children With Cerebral Palsy.

Cerebral Palsy (CP)

This randomized, sham-controlled crossover trial aims to evaluate the immediate effects of spinal manipulation on heart rate variability in children with cerebral palsy. Each participant will attend four experimental sessions conducted on separate days. In two sessions, spinal manipulation will be performed, and in two sessions, a sham procedure will be applied. The order of interventions will be randomized for each participant. Heart rate variability will be recorded before and after each intervention.

Начало: 01.05.2026 Край: 01.11.2026 Възраст: 4–18 г.

Ukraine International Clinic of Rehabilitation, Ukraine NCT07504640

Предстои набиране Фаза 4

Diphenhydramine as an Adjunct to Moderate Sedation for Procedural First Trimester Abortions

Pain Abortion Anxiety

This single center, double blind, randomized controlled trial will evaluate whether adding intravenous diphenhydramine to a standard moderate sedation regimen improves pain control during first trimester procedural abortion. Participants undergoing uterine aspiration at less than 13 weeks gestation will be randomized 1 to 1 to receive standard moderate sedation with midazolam and fentanyl plus either diphenhydramine 50 mg intravenously or matching placebo. The primary outcome is participant reported pain during uterine aspiration measured by a 100 mm Visual Analog Scale.

Начало: 01.05.2026 Край: 01.02.2027 Възраст: от 18 г.

University of Rochester NCT07542730

Предстои набиране

Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis

Systemic Scleroderma

This study is a single-center, single-arm, open-label, exploratory clinical trial. A total of 30 patients with diffuse cutaneous systemic sclerosis (dcSSc) will be enrolled. A historical control cohort will be established to evaluate the efficacy and safety of Firsekibart by comparing with historical data.

Начало: 01.05.2026 Край: 01.12.2028 Възраст: 18–70 г.

China Tongji Hospital NCT07502105

Предстои набиране Фаза 3

Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists

Asthma

This is a study comparing CHF 5993 pMDI HFA-152a with CHF 1535 pMDI HFA-134a in Chinese patients with asthma uncontrolled on medium doses of ICS+LABA.

Начало: 01.05.2026 Край: 17.10.2028 Възраст: 18–75 г.

China Chiesi Farmaceutici S.p.A. NCT07546981

Предстои набиране Фаза 1/2

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

Merkel Cell Carcinoma Merkel Cell Carcinoma, Stage III Merkel Cell Carcinoma, Stage IV

The goal of this clinical trial is to learn if ASTX727 can be combined with retifanlimab to treat Merkel cell cancer. It will also learn about the safety of combining these drugs. The main questions it aims to answer are: * Can the combination shrink cancer and lower the chance of the cancer growing or spreading? * Is the combination better than standard of care for Merkel cell cancer? Participants will: * Take oral ASTX727 and retifanlimab through a vein in the arm for about 2 years. * Visit the clinic once every 2 weeks for checkups and tests

Начало: 01.05.2026 Край: 01.05.2031 Възраст: от 18 г.

United States University of Wisconsin, Madison NCT07472322

Предстои набиране

C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome

COVID-19

The purpose of this research is to find out if Positron Emission Tomography (PET) imaging with an investigational drug called C-11 ER176 can help us learn more about Post-COVID Syndrome.

Начало: 01.05.2026 Край: 01.12.2027 Възраст: от 18 г.

United States Mayo Clinic NCT07527130

Предстои набиране Фаза 3

A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease

Atherosclerotic Cardiovascular Disease

The purpose of the study is to evaluate the impact of HRS9531 on major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease. This study adopts an event-driven design and ends when the target number of the primary endpoint event is reached.

Начало: 01.05.2026 Край: 01.06.2031 Възраст: от 18 г.

China Fujian Shengdi Pharmaceutical Co., Ltd. NCT07551492

Предстои набиране Фаза 2

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

Metastatic Prostate Cancer

The study is being done to see if a small daily dose of naltrexone (LDN, 3 mg pill) can help reduce tiredness (fatigue) in men with prostate cancer. All men in this study are being treated with hormone therapy (also called androgen deprivation therapy, or ADT). Some may also be taking newer hormone medicines such as apalutamide, daralutamide, enzalutamide, or abiraterone.

Начало: 01.05.2026 Край: 01.01.2029 Възраст: от 18 г.

University of Arkansas NCT07224009

Предстои набиране

Oxford Luteal Dysfunction and Placental Insufficiency Study

Pre-eclampsia

High blood pressure (BP) affects approximately 1 in 10 pregnancies. About half of women with high blood pressure in pregnancy develop a serious complication called preeclampsia, which kills over 70,000 women and 500,000 babies every year worldwide. Despite its devastating impact, scientists know little about preeclampsia prevention or treatment. Research has shown that preeclampsia results mainly from an abnormal attachment of the placenta to the lining of the womb. In the first 8 weeks of pregnancy, placental attachment depends on the release of hormones (for example, progesterone) by a gland in the ovary called the corpus luteum. Low blood levels of progesterone in early pregnancy are associated with a reduced chance of having a live baby and higher risk of miscarriage. Giving progesterone to women at risk of miscarriage in early pregnancy reduces their chance of developing preeclampsia by nearly 40%. These results highlight the crucial role of the corpus luteum in normal pregnancy, but there is a need for high-quality studies to identify women whose corpus luteum may be defective. Giving these women medicines to treat corpus luteal defects may lead to normal attachment of the placenta, reducing the risk of pregnancy complications such as preeclampsia. The investigators propose a study that will investigate whether ultrasound features of the corpus luteum and blood and urine levels of corpus luteal hormones may predict preeclampsia.

Начало: 01.05.2026 Край: 01.01.2027 Възраст: от 16 г.

United Kingdom University of Oxford NCT07072052

Предстои набиране

Plasma Therapy for Scar Management: A Prospective Study

Wound Healing

This study is a prospective, multicenter, real-world observational study. It aims to evaluate whether adding plasma device therapy to standard scar care is effective and safe for treating various types of scars, including hypertrophic scars, keloids, atrophic scars, postoperative scars, burn scars, and post-traumatic scars. A total of 400 patients receiving standard scar care plus plasma therapy will be enrolled from multiple hospitals across China. Their outcomes will be compared with 400 matched patients who received standard scar care alone. The main outcomes include change in Vancouver Scar Scale (VSS) score, pruritus relief, pain relief, scar thickness reduction, patient satisfaction, recurrence rate at 6 months, and any side effects. Patients will be followed for up to 6 months after treatment completion.

Начало: 01.05.2026 Край: 31.12.2026

First Affiliated Hospital, Sun Yat-Sen University NCT07548593

Предстои набиране

Optimization and Validation of Electric Acoustic Stimulation (EAS) Mapping as a Function of Residual Hearing After CI-Implantation

Fitting Methods by EAS Patients

The aim of this clinical study is to investigate how the fitting of an EAS (electrical acoustic stimulation) based on electrocochleography (ECochG) thresholds compares to fitting based on pure tone audiogram thresholds in terms of speech intelligibility in quiet and noise. The personal feedback from the study participants regarding the question of better fitting and the resulting sound quality should also be included in the analysis.

Начало: 01.05.2026 Край: 01.11.2027 Възраст: 18–85 г.

Luzerner Kantonsspital NCT07476079

Предстои набиране Фаза 4

Outcomes of CTAK Surgery

Keratoconus Corneal Ectasia

Measuring quality of vision and quality of life outcomes using a validated questionnaire in participants undergoing CTAK surgery for corneal ectasia

Начало: 01.05.2026 Край: 01.01.2031 Възраст: 18–85 г.

United States Stanford University NCT07474870

Предстои набиране

Effect of World Health Organization Labour Care Guide On Reducing Cesarean Section Rates

Labour

After taking informed consent for participation in the study, all selected cases will be divided into two groups by lottery method. In group A, patients will receive care using WHO Labour Care Guide while in group B, patients will be monitored using WHO partograph.

Начало: 01.05.2026 Край: 01.12.2026 Възраст: 18–45 г.

Pak Emirates Military Hospital NCT07550439

Предстои набиране Фаза 2/3

Effects of VALsartan On atRIAl Mitral Regurgitation: A Pilot Randomized Controlled Trial

Atrial Functional Mitral Regurgitation

The goal of this clinical trial is to learn whether valsartan can slow the progression of atrial functional mitral regurgitation (AFMR) in adults with preserved left ventricular ejection fraction. The study will also evaluate the safety and tolerability of valsartan in this population. The main questions it aims to answer are: * Does treatment with valsartan reduce the progression of atrial functional mitral regurgitation compared with placebo? * Does valsartan have favorable effects on mitral valve leaflet remodeling and related cardiac structure and function? * Is valsartan safe and well tolerated in patients with atrial functional mitral regurgitation who do not currently require angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Researchers will compare valsartan to a placebo (a look-alike substance with no active drug) to see if valsartan reduces the progression of atrial functional mitral regurgitation and improves clinical and imaging outcomes. Participants will: * Take valsartan or placebo twice daily for 12 months, with dose adjustments based on blood pressure, kidney function, and tolerance * Undergo 3D echocardiography at baseline, 6 months, and 12 months * Complete a 6-minute walk test at baseline and 12 months * Complete the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 6 months, and 12 months * Undergo 24-hour ambulatory blood pressure monitoring at 1 month * Have regular safety monitoring, including phone follow-up at 7 days, blood tests at 1 month, and blood pressure checks after dose adjustments

Начало: 01.05.2026 Край: 01.12.2029 Възраст: 18–85 г.

Jonathan Beaudoin NCT07539298

1 … 170 171 172 173 174 … 240